FDA Approves Merck’s Keytruda with Chemotherapy for Advanced Mesothelioma

Sep 18, 2024, 10:48 AM

The FDA has approved Merck’s Keytruda (pembrolizumab) in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). This FDA approval marks a significant advancement for patients suffering from this rare and aggressive form of lung cancer.